Literature DB >> 1131654

Cellular immunity in cancer: comparison of delayed hypersensitivity skin tests in three common cancers.

P M Bolton, A M Mander, J M Davidson, S L James, R G Newcombe, L E Hughes.   

Abstract

Cellular immunity was studied in three homogenous groups of patients with cancer to determine whether the pattern of depression of immune competence varied between solid tumours with different patterns of clinical behaviour. Delayed hypersensitivity skin responses were measured in patients with carcinoma of the breast, stomach, and colon and matched controls. Response to 2,4-dinitrochlorobenzene (DNCB) was used as an indication of primary responses and the Mantoux reaction as an index of recall responses. Responses were diminished in all three cancer groups, but there were significant differences between each type of cancer and even between different control groups. Cellular immunity was lost earliest and to the greatest extent in patients with colonic cancers and tended to be retained until a late stage in breast cancer, with gastric cancer occupying an intermediate position. Thus, while there was some degree of correlation between depressed immunity and prognosis our results gave no evidence that general host immune competence could explain the worse prognosis of gastric than colonic cancer. Paradoxical findings in patients with breast cancer suggested a great complexity in the host tumour interaction. Assessments of immune competence in cancer patients must be related to specific types of neoplasms with appropriate control groups if the results are to be meaningful.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1131654      PMCID: PMC1673694          DOI: 10.1136/bmj.3.5974.18

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  Studies on delayed hypersensitivity in Hodgkin's disease.

Authors:  A C AISENBERG
Journal:  J Clin Invest       Date:  1962-11       Impact factor: 14.808

2.  Relation of cell-mediated immunity in women with genital tract cancer to origin, histology, clinical stage and subsequent behaviour of neoplasm.

Authors:  S K Khoo; E V Mackay
Journal:  J Obstet Gynaecol Br Commonw       Date:  1974-03

3.  Impaired immunologic reactivity and recurrence following cancer surgery.

Authors:  F R Eilber; D L Morton
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

4.  Delayed hypersensitivity in cancer patients: cutaneous and in vitro lymphocyte response to specific antigens.

Authors:  H S Nelson
Journal:  J Natl Cancer Inst       Date:  1969-05       Impact factor: 13.506

5.  Immunologic responses in cancer patients.

Authors:  A C Solowey; F T Rapaport
Journal:  Surg Gynecol Obstet       Date:  1965-10

6.  Cellular immunity, peripheral blood lymphocyte count and pathological staging of tumours in the gastrointestinal tract.

Authors:  G Bone; I Lauder
Journal:  Br J Cancer       Date:  1974-09       Impact factor: 7.640

  6 in total
  10 in total

1.  Chemotherapy, a double agent in respect of immune functions.

Authors:  G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

Review 2.  Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 3.  Nutrition in the cancer patient: a review.

Authors:  J W Dickerson
Journal:  J R Soc Med       Date:  1984-04       Impact factor: 5.344

4.  Significance of tumour mass on T-lymphocyte levels in patients with gastrointestinal cancer.

Authors:  H S Shukla; R H Whitehead; L E Hughes
Journal:  Gut       Date:  1979-08       Impact factor: 23.059

5.  Long-term (5-11 years) follow-up of general immune competence in breast cancer. I. Pre-treatment levels with reference to micrometastasis.

Authors:  H S Shukla; L E Hughes; R H Whitehead; R G Newcombe
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Long-term follow-up of general immune competence in breast cancer. II. Sequential pre- and post-treatment levels: a 10 year study.

Authors:  H S Shukla; L E Hughes; R H Whitehead; R G Newcombe
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Dissociation between tumour resistance and delayed-type hypersensitivity to tumour-associated antigens in the mouse.

Authors:  D C Henderson; D Parker; J L Turk
Journal:  Immunology       Date:  1980-01       Impact factor: 7.397

Review 8.  Adjuvant treatment of colorectal cancer. Current status and concepts.

Authors:  U F Metzger; B C Ghosh; D L Kisner
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Premorbid psychological factors as related to cancer incidence.

Authors:  B H Fox
Journal:  J Behav Med       Date:  1978-03

10.  Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages.

Authors:  U Elsässer-Beile; S von Kleist; W Sauther; H Gallati; J S Mönting
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.